Although combination therapy with the mTOR inhibitor sapanisertib and Aurora A kinase inhibitor alisertib (MLN8237) resulted in marginal clinical benefit among patients with advanced solid tumors, correlative analyses indicated that apoptotic response and tumor immune cell infiltrate may affect clinical outcomes.
CU Anschutz
Academic Office One
12631 East 17th Avenue
8601
Aurora, CO 80045